Nguyen Tuan 4

What Happened
Nguyen Tuan, Chief Financial Officer of Arbutus Biopharma (ABUS), received equity awards on 2026-02-02: 73,500 restricted stock units (RSUs) and 188,400 derivative awards (option-type grant). Both awards are reported as acquisitions at $0.00 (standard for grants). The RSUs convert to one common share per RSU upon vesting; the derivative award is an option-like grant that vests over time.

Key Details

• Transaction date: 2026-02-02; transaction code: A (award/grant). Report filed 2026-02-02 (timely).
• Reported acquisition price: $0.00 for both grants. (F2: filing also references the closing market price on grant date.)
• RSUs: 73,500 RSUs (F1). Vest in three equal annual installments beginning one year from grant; on each vesting date shares will automatically be sold as needed to satisfy tax withholding in a non‑discretionary transaction.
• Derivative/option: 188,400 shares (reported as a derivative) (F3). Vests over four years with 1/48th vesting in substantially equal monthly installments starting one month after grant.
• Shares owned after the transactions: not specified in the provided excerpt of the filing.
• Filing timeliness: Filed same day as the report date (not late).

Context

• RSUs represent a contingent right to receive shares at vesting; the derivative award is an option-style grant that must vest before shares can be acquired.
• The automatic sale for tax withholding (non-discretionary) means some vested shares may be sold immediately to cover taxes—this is administrative, not a discretionary sale by the insider.
• These are standard equity compensation awards to an executive and do not by themselves indicate a buying or selling signal.